Announced Tue, 7 Jul · 16:09 IST
Quarterly Reg 74(5) certificate filed with BSE, CDSL and NSDL for June 2026
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.3%1-day move
₹41.49
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-2.3-1.2-1.4-2.4-1.2-2.7————
Up moveDown movePending
AI summary
Sandu Pharmaceuticals submitted a Regulation 74(5) compliance certificate to BSE, CDSL, and NSDL covering the quarter ended 30 June 2026. The certificate was issued by their Registrar and Share Transfer Agent, MUFG Intime India Pvt. Ltd, confirming that shares received from depository participants for dematerialisation were properly accepted or rejected within required timelines, with the depository name recorded as the registered owner. This is a standard recurring compliance requirement under SEBI depository rules.
Likely market impact
Routine quarterly compliance filing with no material impact on shareholders or stock price.